Published in Proc Natl Acad Sci U S A on March 30, 1999
The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97
Immunotoxins for targeted cancer therapy. AAPS J (2006) 1.86
A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci U S A (2006) 1.53
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther (2012) 1.27
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res (2011) 1.25
Advances in anticancer immunotoxin therapy. Oncologist (2015) 1.22
Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine. Clin Vaccine Immunol (2012) 1.12
Ribosome-inactivating proteins: from plant defense to tumor attack. Toxins (Basel) (2010) 1.07
Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest (2008) 1.02
Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication. Vaccine (2010) 1.02
Toxin-based therapeutic approaches. Toxins (Basel) (2010) 1.00
Passive and active vaccination strategies to prevent ricin poisoning. Toxins (Basel) (2011) 0.98
Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma. PLoS One (2012) 0.95
Circular DNA and DNA/RNA hybrid molecules as scaffolds for ricin inhibitor design. J Am Chem Soc (2007) 0.94
Transition state analogues rescue ribosomes from saporin-L1 ribosome inactivating protein. Biochemistry (2009) 0.90
Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels. Am J Pathol (2010) 0.86
Natural products synthesis: enabling tools to penetrate Nature's secrets of biogenesis and biomechanism. J Org Chem (2011) 0.85
NK cells in the tumor microenvironment. Crit Rev Oncog (2014) 0.84
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med (2013) 0.81
The first alpha helix of interleukin (IL)-2 folds as a homotetramer, acts as an agonist of the IL-2 receptor beta chain, and induces lymphokine-activated killer cells. J Exp Med (2000) 0.81
Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity. MAbs (2012) 0.79
Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. J Transl Med (2014) 0.78
Interleukin-7 and interleukin-15 for cancer. J Cancer (2014) 0.78
Immunotoxins: a promising treatment modality for metastatic melanoma? Ochsner J (2010) 0.77
Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells. Oncotarget (2016) 0.77
Disruption of the putative vascular leak peptide sequence in the stabilized ricin vaccine candidate RTA1-33/44-198. Toxins (Basel) (2013) 0.76
Collapse of the Microbiome, Emergence of the Pathobiome, and the Immunopathology of Sepsis. Crit Care Med (2017) 0.76
Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model. Hum Vaccin Immunother (2015) 0.75
High efficacy vasopermeability drug candidates identified by screening in an ex ovo chorioallantoic membrane model. Sci Rep (2015) 0.75
Clinical targeting recombinant immunotoxins for cancer therapy. Onco Targets Ther (2017) 0.75
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology (1997) 2.07
Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells. Proc Natl Acad Sci U S A (1997) 1.82
Structure of recombinant ricin A chain at 2.3 A. Protein Sci (1993) 1.41
Activation-dependent recognition by hematopoietic cells of the LDV sequence in the V region of fibronectin. J Cell Biol (1992) 1.25
Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor. Proc Natl Acad Sci U S A (1988) 1.22
Viper venom disintegrins and related molecules. Proc Soc Exp Biol Med (1998) 1.21
Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin. J Cell Sci (1994) 1.09
Immunotoxins: magic bullets or misguided missiles? Immunol Today (1993) 1.08
Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood (1998) 1.06
The crystal structure of Pseudomonas aeruginosa exotoxin domain III with nicotinamide and AMP: conformational differences with the intact exotoxin. Proc Natl Acad Sci U S A (1995) 1.05
What have snakes taught us about integrins? Cell Mol Life Sci (1998) 0.98
Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp Cell Res (1993) 0.97
A novel cyclic pentapeptide inhibits alpha 4 beta 1 and alpha 5 beta 1 integrin-mediated cell adhesion. J Biol Chem (1993) 0.94
Clinical toxicity of interleukin-2. Drug Saf (1992) 0.93
Substitutions of proline 42 to alanine and methionine 46 to asparagine around the RGD domain of the neurotoxin dendroaspin alter its preferential antagonism to that resembling the disintegrin elegantin. J Biol Chem (1996) 0.92
Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents. J Med Chem (1997) 0.91
The toxicity of chemically deglycosylated ricin A-chain in mice. Int J Immunopharmacol (1992) 0.89
Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro. Am J Respir Cell Mol Biol (1992) 0.87
Systematic deletion analysis of ricin A-chain function. Single amino acid deletions. J Biol Chem (1995) 0.86
LDV: a novel cell adhesion motif recognized by the integrin alpha 4 beta 1. Biochem Soc Trans (1991) 0.85
An in vivo model to study immunotoxin-induced vascular leak in human tissue. J Immunother (1999) 0.84
Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice. Cancer Immunol Immunother (1989) 0.83
Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo. Cancer Res (1989) 0.82
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol (1991) 0.81
Novel psi-S-CH2 peptide-bond replacement and its utilization in the synthesis of nonpeptidic surrogates of the Leu-Asp-Val sequence that exhibit specific inhibitory activities on CD4+ T cell binding to fibronectin. Int J Pept Protein Res (1994) 0.80
Amino acids and peptides. XXXII: A bifunctional poly(ethylene glycol) hybrid of fibronectin-related peptides. Biochem Biophys Res Commun (1997) 0.80
NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin-2-induced capillary leak syndrome in healthy mice. J Immunother Emphasis Tumor Immunol (1995) 0.79
Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells. Int J Immunopharmacol (1997) 0.78
Synaptotagmin I functions as a calcium regulator of release probability. Nature (2001) 5.96
Cell surface immunoglobulin. II. Isolation and characterization of immunoglobulin from mouse splenic lymphocytes. J Exp Med (1971) 5.80
Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature (1988) 5.56
A conformational switch in syntaxin during exocytosis: role of munc18. EMBO J (1999) 5.07
Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc Natl Acad Sci U S A (1984) 4.62
T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J Exp Med (1982) 4.51
Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1. J Exp Med (1985) 4.47
Three-dimensional structure of an evolutionarily conserved N-terminal domain of syntaxin 1A. Cell (1998) 3.40
Immunoglobulin-receptors revisited. Science (1975) 3.38
Biochemical evidence linking the GIX thymocyte surface antigen to the gp69/71 envelope glycoprotein of murine leukemia virus. J Exp Med (1975) 3.31
Cell surface immunoglobulin. XI. The appearance of an IgD-like molecule on murine lymphoid cells during ontogeny. J Exp Med (1975) 3.26
Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J Exp Med (1988) 3.16
Three-dimensional structure of the synaptotagmin 1 C2B-domain: synaptotagmin 1 as a phospholipid binding machine. Neuron (2001) 3.10
Vam3p structure reveals conserved and divergent properties of syntaxins. Nat Struct Biol (2001) 2.92
Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol (2001) 2.87
Cell surface immunoglobulin. IV. Distribution among thymocytes, bone mrrow cells, and their derived populations. J Exp Med (1972) 2.50
B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci U S A (1985) 2.41
Functional and ontogenetic analysis of murine CD45Rhi and CD45Rlo CD4+ T cells. J Immunol (1990) 2.41
Isolation of heavy and light chains of immunoglobulin from the surfaces of lymphoid cells. J Immunol (1971) 2.35
Ca2+ binding to synaptotagmin: how many Ca2+ ions bind to the tip of a C2-domain? EMBO J (1998) 2.31
Bipartite Ca2+-binding motif in C2 domains of synaptotagmin and protein kinase C. Science (1996) 2.31
Organization of the immune response genes. Science (1979) 2.18
Synaptotagmins: C2-domain proteins that regulate membrane traffic. Neuron (1996) 2.14
Solution structures of the Ca2+-free and Ca2+-bound C2A domain of synaptotagmin I: does Ca2+ induce a conformational change? Biochemistry (1998) 2.11
Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology (1997) 2.07
Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol (1998) 1.96
The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol (2001) 1.93
The differential expression of homing and adhesion molecules on virgin and memory T cells in the mouse. Cell Immunol (1991) 1.88
Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci U S A (1980) 1.85
B cell-stimulatory factor 1 (BSF-1) promotes growth of helper T cell lines. J Exp Med (1986) 1.82
Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol (2002) 1.81
Selective interaction of complexin with the neuronal SNARE complex. Determination of the binding regions. J Biol Chem (2000) 1.79
Association of a beta2-microglobulin-like subunit with H-2 and TL alloantigens on murine thymocytes. J Immunol (1975) 1.79
Synthesis of germ-line gamma 1 immunoglobulin heavy-chain transcripts in resting B cells: induction by interleukin 4 and inhibition by interferon gamma. Proc Natl Acad Sci U S A (1989) 1.78
Structural similarities between a product of the T/t-locus isolated from sperm and teratoma cells, and H-2 antigens isolated from splenocytes. Proc Natl Acad Sci U S A (1975) 1.76
Mechanism of phospholipid binding by the C2A-domain of synaptotagmin I. Biochemistry (1998) 1.76
The protein products of the murine 17th chromosome: genetics and structure. Adv Immunol (1978) 1.76
Induction of B cell differentiation by T cell factors. I. Stimulation of IgM secretion by products of a T cell hybridoma and a T cell line. J Immunol (1981) 1.73
Activation of antigen-specific B cells: role of T cells, cytokines, and antigen in induction of growth and differentiation. Proc Natl Acad Sci U S A (1983) 1.73
The relationship between surface immunoglobulin isotype and immune function of murine B lymphocytes. I. Surface immunoglobulin isotypes on primed B cells in the spleen. J Exp Med (1977) 1.71
Augmenting neurotransmitter release by enhancing the apparent Ca2+ affinity of synaptotagmin 1. Proc Natl Acad Sci U S A (2005) 1.71
Cell surface immunoglobulin. X. Identification of an IgD-like molecule on the surface of murine splenocytes. J Exp Med (1974) 1.70
Immunotoxins: a new approach to cancer therapy. Science (1983) 1.65
T-cell-derived lymphokines that induce IgM and IgG secretion in activated murine B cells. Immunol Rev (1984) 1.65
Highly purified CD25- resting T cells cannot be infected de novo with HIV-1. Proc Natl Acad Sci U S A (1997) 1.62
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res (1995) 1.62
Expression of murine leukemia virus envelope glycoprotein gp69/71 on mouse thymocytes. Evidence for two structural variants distinguished by presence vs. absence of GIX antigen. J Exp Med (1975) 1.62
Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol (1999) 1.61
Synaptotagmin-syntaxin interaction: the C2 domain as a Ca2+-dependent electrostatic switch. Neuron (1997) 1.60
IgD and B cell differentiation. Immunol Rev (1977) 1.59
Clonal analysis of B cells induced to secrete IgG by T cell-derived lymphokine(s). J Exp Med (1984) 1.58
Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur J Immunol (1994) 1.57
B-cell tolerance. II. Trinitrophenyl human gamma globulin-induced tolerance in adult and neonatal murine B cells responsive to thymus-dependent and independent forms of the same hapten. J Exp Med (1977) 1.57
Cell surface immunoglobulin. XX. Antibody responsiveness of subpopulations of B lymphocytes bearing different isotypes. J Exp Med (1977) 1.57
Lymphokine-induced IgM secretion by clones of neoplastic B cells. Nature (1983) 1.56
Cell surface immunoglobulin. V. Release from murine splenic lymphocytes. J Exp Med (1972) 1.56
T cell-derived B cell growth and differentiation factors. Dichotomy between the responsiveness of B cells from adult and neonatal mice. J Exp Med (1983) 1.54
Characterization of the physical interaction between antigen-specific B and T cells. J Immunol (1986) 1.53
Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immunol Rev (1982) 1.52
Relationship between inspiratory pressure and tidal volume in the anesthetized canine. Lab Anim Sci (1998) 1.52
Interleukin 4 mediates autocrine growth of helper T cells after antigenic stimulation. Proc Natl Acad Sci U S A (1986) 1.51
Differential susceptibility of neonatal and adult murine spleen cells to in vitro induction of B-cell tolerance. J Exp Med (1976) 1.50
The evolutionary pressure to inactivate. A subclass of synaptotagmins with an amino acid substitution that abolishes Ca2+ binding. J Biol Chem (1997) 1.44
Epitopes on CD45R [T200] molecules define differentiation antigens on murine B and T lymphocytes. J Mol Cell Immunol (1988) 1.43
Absence of H-2 antigens capable of reacting with cytotoxic T cells on a teratoma line expressing a T/t locus antigen. Proc Natl Acad Sci U S A (1975) 1.43
Structural studies on the murine Ia alloantigens--III. Tryptic peptide comparisons of allelic products of the I-E/C sub-region. Mol Immunol (1979) 1.42
Large-pore hemodialysis in acute endotoxin shock. Crit Care Med (1999) 1.41
Protection of mice against experimental murine mycoplasmosis by a Mycoplasma pulmonis immunogen in lysogenized Escherichia coli. Vaccine (1994) 1.40
Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol (1997) 1.39
Cell surface immunoglobulin. VII. Synthesis, shedding, and secretion of immunoglobulin by lymphoid cells of germ-free mice. J Exp Med (1974) 1.38
The C2B domain of synaptotagmin I is a Ca2+-binding module. Biochemistry (2001) 1.38
HIV-infected cells are killed by rCD4-ricin A chain. Science (1988) 1.37
Structural studies on the murine Ia alloantigens. V. Evidence that the structural gene for the I-E/C beta polypeptide is encoded within the I-A subregion. J Exp Med (1979) 1.34
Characterization of a spontaneous murine B cell leukemia (BCL1). I. Cell surface expression of IgM, IgD, Ia, and FcR. J Immunol (1979) 1.33
Cell surface immunoglobulin. XVIII. Functional differences of B lymphocytes bearing different surface immunoglobulin isotypes. J Exp Med (1976) 1.33
B-cell tolerance. III. Effect of papain-mediated cleavage of cell surface IgD on tolerance susceptibility of murine B cells. J Exp Med (1977) 1.32
NMR analysis of the structure of synaptobrevin and of its interaction with syntaxin. J Biomol NMR (1999) 1.31
Immunobiology of a spontaneous murine B cell leukemia (BCL1). Immunol Rev (1979) 1.31
Cancer dormancy: opportunities for new therapeutic approaches. Nat Med (1997) 1.31
Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc Natl Acad Sci U S A (1989) 1.31
Synthesis, biochemistry and dynamics of cell surface immunoglobulin on lymphocytes. Fed Proc (1973) 1.31
Demonstration and assaying of IgG antibodies in tissues and on cells by labeled staphylococcal protein A. J Immunol Methods (1975) 1.30
Characterization of a B cell defect in the NZB mouse manifested by an increased ratio of surface IgM to IgD. J Immunol (1978) 1.29
The LDL receptor clustering motif interacts with the clathrin terminal domain in a reverse turn conformation. J Cell Biol (1998) 1.29
Synthesis, transport, dynamics and fate of cell surface Ig and alloantigens in murine lymphocytes. Transplant Rev (1973) 1.28
Structural studies on the murine Ia alloantigens. IV. NH2-terminal sequence analysis of allelic products of the I-A and I-E/C subregions. J Immunol (1979) 1.28
BCL1, a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of tumor. Immunol Rev (1979) 1.27
Isolation and characterization of a molecular complex containing Thy-1 antigen from the surface of murine thymocytes and T cells. Eur J Immunol (1973) 1.27
Murine B cell leukemia (BCL1): organ distribution and kinetics of growth as determined by fluorescence analysis with an anti-idiotypic antibody. J Immunol (1979) 1.27
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 1.27
Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol (1994) 1.26
The effect of anti-immunoglobulin antibodies on the in vitro proliferation and differentiation of normal and neoplastic murineB cells. J Immunol (1980) 1.26
Memory T cells are anergic to the superantigen staphylococcal enterotoxin B. J Exp Med (1992) 1.25
Immunoglobulin synthesis and secretion by cells in the mouse thymus that do not bear theta antigen. Proc Natl Acad Sci U S A (1973) 1.24
Relationship between trinitrophenyl and H-2 antigens on trinitrophenyl-modified spleen cells. I. H-2 antigens on cells treated with trinitrobenzene sulfonic acid are derivatized. J Immunol (1977) 1.23
The relationship between surface immunoglobulin isotype and immune function of murine B lymphocytes II. Surface immunoglobulin isotopes on unprimed B cells in the spleen. J Exp Med (1977) 1.23
Immunoglobulins and alloantigens on the surface of lymphoid cells. Biochim Biophys Acta (1975) 1.23
The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Mol Immunol (1996) 1.23
Immunotoxins: an update. Annu Rev Immunol (1996) 1.22